Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class

Clin Microbiol Infect. 2012 Nov;18(11):E485-90. doi: 10.1111/1469-0691.12011. Epub 2012 Sep 27.

Abstract

We have studied transmitted drug resistance (TDR) in 1.864 antiretroviral-naïve patients entering CoRIS (Spain) during 2007-2010. An overall 8.58% TDR was observed (3.92%, nucleoside reverse transcriptase inhibitors (NRTIs); 3.86%, non-nucleoside reverse transcriptase inhibitors (NNRTIs); 2.31%, protease inhibitors), with a significant decreasing trend over time for NNRTIs (5.53%, 2007; 2.45%, 2010; p for trend = 0.044). Non-B subtype prevalence was 15.93%, with a significant increase (11.95%, 2007; 18.14%, 2010; p for trend = 0.018), mainly related to immigration. Having no formal education increased the risk of TDR to NNRTIs (OR, 7.26), and carrying a non-B subtype reduced the risk of TDR to NRTIs (OR, 0.27). These findings may have important implications for treatment guidelines and laboratory testing recommendations.

MeSH terms

  • Adult
  • Anti-Retroviral Agents / administration & dosage
  • Anti-Retroviral Agents / pharmacology*
  • Drug Resistance, Viral*
  • Female
  • Genotype
  • HIV / drug effects*
  • HIV / isolation & purification
  • HIV Infections / epidemiology
  • HIV Infections / transmission*
  • HIV Infections / virology*
  • HIV Reverse Transcriptase / genetics
  • Humans
  • Male
  • Mutation, Missense*
  • Nucleosides / administration & dosage
  • Nucleosides / pharmacology
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Spain / epidemiology

Substances

  • Anti-Retroviral Agents
  • Nucleosides
  • Reverse Transcriptase Inhibitors
  • HIV Reverse Transcriptase